podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 17/22 Podcast
  4. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
Background: The potential anti-cancer effects of mammalian target
of rapamycin (mTOR) inhibitors are being intensively studied. To
date, however, few randomised clinical trials (RCT) have been
performed to demonstrate antineoplastic effects in the pure
oncology setting, and at present, no oncology endpoint-directed RCT
has been reported in the high-malignancy risk population of
immunosuppressed transplant recipients. Interestingly, since mTOR
inhibitors have both immunosuppressive and anti-cancer effects,
they have the potential to simultaneously protect against
immunologic graft loss and tumour development. Therefore, we
designed a prospective RCT to determine if the mTOR inhibitor
sirolimus can improve hepatocellular carcinoma (HCC)-free patient
survival in liver transplant (LT) recipients with a pre-transplant
diagnosis of HCC. Methods/Design: The study is an open-labelled,
randomised, RCT comparing sirolimus-containing versus
mTOR-inhibitor- free immunosuppression in patients undergoing LT
for HCC. Patients with a histologically confirmed HCC diagnosis are
randomised into 2 groups within 4-6 weeks after LT; one arm is
maintained on a centre-specific mTOR-inhibitor- free
immunosuppressive protocol and the second arm is maintained on a
centre-specific mTOR-inhibitor- free immunosuppressive protocol for
the first 4-6 weeks, at which time sirolimus is initiated. A
2(1/2)-year recruitment phase is planned with a 5-year follow-up,
testing HCC-free survival as the primary endpoint. Our hypothesis
is that sirolimus use in the second arm of the study will improve
HCC-free survival. The study is a non-commercial
investigator-initiated trial (IIT) sponsored by the University
Hospital Regensburg and is endorsed by the European Liver and
Intestine Transplant Association; 13 countries within Europe,
Canada and Australia are participating.

Weitere Episoden

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

vor 15 Jahren
Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

vor 15 Jahren
Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

vor 15 Jahren
Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

vor 15 Jahren
Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

vor 15 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Er
Erasmus2

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz